Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic ...
IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approval SP-26 ketamine implants nearing first animal studies SARASOTA, FL, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” “ …